Business Description
Grace Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : CA00430K4028
Share Class Description:
FRA:L8S: Ordinary SharesCompare
Compare
Traded in other countries / regions
ACST.USAACST.CanadaL8S.Germany IPO Date
2014-09-24Description
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 808.71 | |||||
| Equity-to-Asset | 0.85 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 27.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34.7 | |||||
| 3-Year FCF Growth Rate | 34.2 | |||||
| 3-Year Book Growth Rate | -20 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 72.48 | |||||
| 9-Day RSI | 68.5 | |||||
| 14-Day RSI | 65.05 | |||||
| 6-1 Month Momentum % | -4.32 | |||||
| 12-1 Month Momentum % | 18.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.86 | |||||
| Quick Ratio | 7.86 | |||||
| Cash Ratio | 7.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -29.4 | |||||
| Shareholder Yield % | -21.94 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -18.08 | |||||
| ROA % | -15.45 | |||||
| ROIC % | -22.55 | |||||
| 3-Year ROIIC % | 1.56 | |||||
| ROC (Joel Greenblatt) % | -22722.79 | |||||
| ROCE % | -18.5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.54 | |||||
| Price-to-Tangible-Book | 3.12 | |||||
| EV-to-EBIT | -0.59 | |||||
| EV-to-EBITDA | -0.59 | |||||
| EV-to-FCF | -0.91 | |||||
| Price-to-Net-Current-Asset-Value | 3.16 | |||||
| Price-to-Net-Cash | 3.52 | |||||
| Earnings Yield (Greenblatt) % | -170.19 | |||||
| FCF Yield % | -31.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Grace Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -1.319 | ||
| Beta | 0.91 | ||
| Volatility % | 69.37 | ||
| 14-Day RSI | 65.05 | ||
| 14-Day ATR (€) | 0.020597 | ||
| 20-Day SMA (€) | 2.78 | ||
| 12-1 Month Momentum % | 18.75 | ||
| 52-Week Range (€) | 1.83 - 3.14 | ||
| Shares Outstanding (Mil) | 10.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Grace Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Grace Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Grace Therapeutics Inc Frequently Asked Questions
What is Grace Therapeutics Inc(FRA:L8S)'s stock price today?
The current price of FRA:L8S is €2.78. The 52 week high of FRA:L8S is €3.14 and 52 week low is €1.83.
When is next earnings date of Grace Therapeutics Inc(FRA:L8S)?
The next earnings date of Grace Therapeutics Inc(FRA:L8S) is 2024-11-13 Est..
Does Grace Therapeutics Inc(FRA:L8S) pay dividends? If so, how much?
Grace Therapeutics Inc(FRA:L8S) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers